Multivalent Fibronectin-Integrin Targeting Agents for Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for bladder cancer, such as live Bacillus Calmette-Guerin (BCG), face challenges including patient hypersensitivity, morbidity, and poor targeting due to urine influx and voiding, while purified proteins require multiple molecules for effective targeting.
Innovation Solution
Development of artificial multivalent fibronectin/integrin targeting agents that do not require microclustering, offering improved binding affinity and uptake rates, and are more stable and soluble than monovalent compositions, using peptides with specific amino acid sequences to target bladder cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live BCG is used to target bladder tumor cells, then the ability to bind exposed tumor cells and trigger anti-tumor immune response is improved, but patient hypersensitivity, morbidity, and risk of infection worsen
Solution Approach 1:
The patent extracts and isolates the fibronectin attachment protein (FAP) from the live BCG bacterium, using only the specific targeting component while eliminating the harmful live bacterial elements that cause hypersensitivity and morbidity. This allows retention of tumor cell binding capability without the adverse immune reactions associated with live BCG.
Solution Approach 2:
The patent creates synthetic peptide copies of the FAP fibronectin-binding domain that replicate the tumor cell targeting function of natural FAP. These synthetic peptides can be engineered with multiple copies (multivalent) to enhance binding affinity while avoiding the complications of using live bacteria or even purified natural proteins.
2Object-affected harmful factors
If purified proteins such as FAP are used as targeting substitutes, then negative secondary effects of BCG are eliminated, but multiple molecules are required to be tied together to achieve meaningful uptake rates
Solution Approach 1:
The patent combines multiple fibronectin-binding peptide sequences into a single synthetic multivalent protein construct. By merging several binding sites into one molecule, the invention achieves high uptake rates without requiring separate molecules to be physically tied together or microclustered, simplifying the overall therapeutic design.
Solution Approach 2:
The patent creates composite peptide structures that integrate multiple fibronectin-binding domains (such as FBS1 and FBS2 from FAP) into a single functional unit. This composite approach allows the therapeutic agent to exhibit enhanced binding avidity through multiple simultaneous interactions with integrin-bound fibronectin on tumor cells.
3Device complexity
If monovalent compositions are used, then simplicity is maintained, but effective binding affinity and rate of uptake are insufficient
Solution Approach 1:
The patent changes the valency parameter of the targeting agent from monovalent to multivalent by incorporating multiple fibronectin-binding peptide sequences (e.g., 2-10 copies) into each protein construct. This parameter change dramatically increases binding affinity through avidity effects, where multiple weak interactions collectively create strong overall binding to integrin-bound fibronectin on tumor cell surfaces.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multivalent agents effectively bind and internalize by bladder cancer cells, enhancing therapeutic delivery and reducing side effects by selectively targeting exposed tumor cells while shielding normal cells.
Implementation Method 1
therapeutic agents that specifically target integrin-bound fibronectin on the surface of bladder cancer cells
Implementation Method 2
the compositions of the invention have improved effective binding affinity (avidity) and rate of uptake
Data Source
AI summary
The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.